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Abstract
Breast cancer is the second leading cause of cancer deaths in women. Several drugs including cisplatin and carboplatin have
shown tremendous effectivity in reducing cancer; however development of drug resistance by breast cancer cells to overcome
cytotoxic insults and recurrence of the disease is a major concern at the moment. Andrographolide is a diterpenoid with a potent
anti-inflammatory and anti tumor activity and it ’ s usage in combination therapy would be ideal as it is proven for it ’ s apoptotic
capability in varied number of cells. Antiproliferative and apoptotic activity of andrographolide in triple negative MDA-MB-231 cells
was evaluated by clonogenic assay and flow cytometric analysis. Expression and phosphorylation of proteins were evaluated by
immunoblotting. Our results revealed dose-dependent cytotoxic effects of andrographolide in MDA-MB-231 cells with and without
carboplatin. It resulted in G2/M arrest of cells when treated alone, and further enhanced upon treatment in combination with
carboplatin. Andrographolide alone and in combination with carboplatin enhanced apoptotic cells in early, mid and late stages
and increased expression of DNA damage repair response proteins including FANCJ, FANCD2, RAD51, pRPA32 and p53. The
present study strongly suggests that andrographolide inhibits breast cancer cell proliferation by apoptosis mediated through cell
cycle arrest and up regulation of DNA damage repair response gene expression and shows synergistic effects upon usage in
combination with carboplatin.
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Introduction
Cancer remains the second leading cause of mortality around
the globe with an incidence rate of more than 2.6 million cases
per year [1]. Among the malignancies, breast cancer is the most
prevalent diagnosed neoplasm and the main cause of cancer
death among females, accounting for 23% of the total cancer
case s and 14% of the cancer deaths [2]. In India, breast can-
cer is estimated to be 1.5 lakh (over 10 per cent of all cancers)
new cases during 2016, and overall is the leading cancer [3].
Earlier studies reported that most cancers are triggered by dys-
function of genes encoding for growth factors, growth factor re-
ceptors, anti-apoptotic proteins, transcription factors, and tumor
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suppressors making them a target for the treatment of cancer by
natural products [4]. Despite several breast cancer drugs such as
cisplatin and carboplatin in use, a significant risk of recurrence
and resistance to therapy is observed resulting in treatment of
breast cancer a troublesome affair. Therefore, finding effective
anticancer drugs with minimal side effects and higher efficacy
has been one of the main criteria in cancer research [5]. Com-
binaton therapies have been tried successfully with cisplatin in
various cancer cells and found to be effective in reduction of tu-
mors.
Over the years, scientific research has been focused on identi-
fying the naturally occurring chemopreventive agents, especially
those present in dietary and medicinal plants due to their bioac-
tive molecules [6]. Plant-derived natural products play an im-
portant role in the field of cancer chemotherapy as they had
been a promising source for breakthrough discovery and de-
velopment of chemotherapeutic agents [7]. Plant products such
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as vincristine, vinblastine, paclitaxel, epipodophyllotoxin, cam-
pothecin derivatives etc., are invaluable contributions of nature
to modern medicine [8]. However, the quest to identify new
therapeutic compounds for cancer therapy and management is
a never-ending task.
Andrographis paniculata Nees, belongs to the family of
Acanthaceae, commonly called “King of bitters” is a well-
known plant of traditional Indian and Chinese system of
medicine. Many researchers focused on andrographolide in
recent times due to its amazing therapeutic and medical pr op-
erties. Diterpenoid lactone, a ndrographolide (C20 H30 O5 ), is
the principal bioactive chemical constituent found in A. panicu-
lata which is concentrated in leaves and stem, exhibits diverse
biological activities, such as immunomodulatory, hepatopro-
tective, anti-inflammatory, antiviral, anti-HIV and anti-tumor
etc., [9]. In terms of its potential anticancer properties, andro-
grapholide has been reported to exhibit potent antiproliferative
activity against variety of human cancer cell lines, viz; neu-
roblastoma, melanoma, hepatoma, prostate cancer, and gastric
cancer [10–12]. This compound exerts anticancer activity on
tumor cells by different mechanisms, such as cell-cycle arrest,
cellular migration and angiogenesis and growth factor signal-
ing modulation [13]. It also showed potent antiangiogenic and
immunomodulatory activites in tumor tissues [14]. Androa-
grapholide has been reported to sensitize breast cancer cells to
chemotherapeutic drug cisplatin and exert synergistic effects in
the treatment of cancer [15]. As andrographolide is valuable of
further investigation as a potent anticancer drug entity, a better
understanding of its cellular mechanism of action is warranted.
Therefore, the present study is aimed to evaluate the anti-cancer
effects of andrographolide and understand its molecular mecha-
nism of action in human breast cancer cell lines.
In the present study, we investigated whether andrographolide
could inhibit the growth of breast cancer cells namely triple neg-
ative MDA-MB-231. We found that andrographolide reduced
the proliferation of MDA-MB-231 cells and also showed en-
hanced anti-proliferative effects when treated in combination
with carboplatin. Andrographolide was also found to enhance
the levels of DNA damage repair proteins during co-treatment
of cells with andrographolide and carboplatin.
Materials and methods
Cell Culture
The human breast cancer cells, MDA-MB-231 were procured
from NCCS, Pune, India and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum, 100 µg/ml streptomycin and 100U/ml penicillin. The
cells were maintained at 37◦C and 5% CO2. Mycotest kit (In-
vitrogen) was used to detect mycoplasma contamination and
cells within 8-10 passages were used in the experiments. Stock
solutions of (100mM and 10mM) of andrographolide and car-
boplatin (Sigma, St. Louis, MO) were prepared in DMSO and
stored at −20◦C and subsequently, these stock solutions were
further diluted to required concentration prior to treatment of
cells.
Clonogenic survival assay
6-well dishes in triplicates were plated with triple negative
MDA-MB-231 cells and incubated for overnight for cell at-
tachment and treated with respective concentrations of andro-
grapholide (2,4,6,8,10 µM) and 20 µM carboplatin and allowed
for colony formation by replacement of the medium once in
every three days for 7-12 days. Later colonies were fixed in
methanol, stained with crystal violet and counted using Gene
Tools, Syngene Imaging system [16].
Flow Cytometric Cell Cycle Analysis
MDA-MB-231 cells were seeded into 6-well dishes and pre-
cultured for 24 hrs. The cells were then treated with 15 µ M
Andrographolide and 20 µM Carboplatin alone and both for 12
hrs. The cells were trypsinized, washed with PBS and fixed in
70% ice-cold ethanol. The cells were further washed with PBS
and re-suspended in 1 ml PBS. The cells were then incubated
with RNase A (250 µg/ml) for 30 min and stained with propid-
ium iodide (PI, 10 µg/ml) for 10 min and cell cycle analysis was
performed by flow cytometry (FACS Calibur, BD Biosciences,
CA). A minimum of 10,000 cells per samples were acquired and
analyzed using Cell Quest Pro software [16].
Analysis of Nuclear Morphology
A nuclear morphological study was performed as described. Af-
ter treatment, the cells were collected, washed with PBS, fixed
with 4% formaldehyde for 10 mins and incubated in 500  l of
PBS containing 10 g/ml Propidium Iodide, incubated in dark
for 10 mins, centrifuged and mounted in PBS with 90% glycerol,
1mg/ml anti-fade (paraphenylenediamine) and 0.5mg/ml 4, 6-
diamidino-2-phenylindole (DAPI). The cells were imaged using
Olympus BX51 flourescent microscope at 20X magnification.
Cell apoptosis assay
Cells undergoing apoptosis were assessed using PE-annexin-
V apoptosis detection kit (Dead Cell Apoptosis Kit with An-
nexin V Alexa Fluor
®
488 and PI kit) according to the manu-
facturer’s instruction (Life Technologies Inc.) Briefly, cells were
plated in 6-well plates at a density of 1×105 cells/well and were
treated for 48 h with 15 µM andrographolide, 20 µM carboplatin
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and combination of both. Post treatment, cells were recovered,
washed with binding buffer (BB) and centrifuged. Annexin-
V FITC (10 µl) was added to the pellet and incubated in the
dark for 15 min at room temperature. Subsequently, cells were
washed and re-suspended in BB, and PI solution (20 µg/mL)
was added immediately prior to analysis by flow cytometry. The
flow-cytometric analysis was performed using a FACS Calibur
(BD Biosciences, CA).
Western Blotting
Cells (1×105 cells) were treated with 15 µM andrographolide,
20 µM carboplatin and combination of both for 12 hr for west-
ern blot analysis. After treatment, the cells were collected and
washed with ice cold PBS for two times. Cells were then lysed
in ice-cold lysis buffer (1% Triton X-100, 1 mol L−1 HEPES, 5
M NaCl and 0.5 M EDTA) freshly supplemented with protease
and phosphatase inhibitors (Roche, Germany). The lysates were
then centrifuged at 14,000 g at 4# C for 20 min. Samples were
prepared in 4x SDS-PAGE sample buffer, boiled at 100◦C for
15 min. SDS PAGE was used to resolve denatured samples and
transferred to nitrocellulose membranes, which were later incu-
bated with respective antibodies followed by incubation with
specific HRP-conjugated secondary antibodies. The blots were
then developed by chemiluminescence detection kit. Antibodies
used to the following antigens in the study include: FANC D2,
FANC J and GAPDH (Santa Cruz Biotechnology, Inc.); phospho
RPA, RAD51, p53, Phospho p53 and acetyl p53 (Cell Signalling
Technologies) respectively.
Results
Andrographolide exhibits chemotherapeutic activity
Clonogenic potential of the cell lines was significantly influ-
enced by andrographolide and carboplatin in a dose depen-
dent manner. In cell lines, triple negative MDA-MB-231 andro-
grapholide exhibited growth inhibitory properties with an IC50
value of 4.5 µM (Figure. 1). High sensitivity of triple negative
MDA-MB-231 cell line towards treatment of andrographolide
alone and in combination with carboplatin confirms its sensitiv-
ity and makes an ideal model to undertake chemotherapy based
studies for breast cancer.
Andrographolide treatment induces G2/M arrest of
cells.
Exposure of triple negative MDA-M B-231 cells to andro-
grapholide and combination of both attenuated cell cycle pro-
gression through G2/M phase after 12hr treatme nt compared
to control or carboplatin alone treated cells. Most of the cells
were found to be in S-phase and appeared to progress slowly
towards G2/M phase indicating that the cells were under repli-
cation stress (Figure. 2). The cell cycle arrest at G2/M phase
indicated that andrographolide may have the ability to interfere
with DNA replication directly or indirectly and induce replica-
tion associated DNA damage which in turn may further activate
checkpoint responses to arrest the progression of cell cycle by
blocking mitotic phase entry [17].
Andrographolide treatment and DNA damage
responses
Since andrographolide treatment and combination treatment
with carboplatin affected cell cycle, we hypothesized that it may
increase the expression of DNA damage repair (DDR) proteins
such as FANC J, FANCD2, RAD51, pRPA32, P53 and may
have a role in regulation of expression and phosphorylation
of DDR proteins. For this experiment, triple negative MDA-
MB-231 cells were subjected to 15 µM andrographolide and
20 µM carboplatin and both together. After 12 hr of exposure,
whole cell lysates were normalized with GAPDH for protein
concentrations and probed for different D NA damage repair
proteins. Breast cancer cells treated with andrographolide alone
and in combination with carboplatin both induced ATM/ATR-
mediated DDR as evidenced by enhanced expression of FANC J,
FANCD2 and RAD51. Several studies recognized functional in-
teractions among FANCD2, BRCA2 and Rad51 in stabilization
of stalled replication forks and repair of collapsed forks [18].
Further, earlier studies have shown that replication protein A
(RP A) is phosphorylated at several sites during different stages
of cell cycle, one among them is phosphorylation of RPA-32 at
ser-29 during M-phase which is dephosphorylated at comple-
tion of M-phase [19]. In our study, we found phosphorylation
of RPA-32 indicating that the cells are in M-phase which is in
consistent with cell cycle studies. Further, pRPA32 is known to
induce the expression of p53 which is found enhanced and phos-
phorylated in our observations (Fig 3). Thus, the results indicate
that andrographolide alone or in combination with carboplatin
leads to replication stress-associated DDR, which slows cell
cycle progression though S-phase with the accumulation of cells
in G2/M phases in MDA-MB-231 cells.
Andrographolide induces apoptosis
Further, apoptosis was monitored in triple negative MDA-MB-
231 cells treated with andrographolide, carboplatin and a com-
bination of both by annexin V staining. Figure 4 (a and b), re-
veals an increase of apoptotic cells at early, mid and late stages,
with annexin-V positive cells after 48 hours treatment of MDA-
MB-231 cells. An increased number of cells in early and mid
stages of apoptosis in andrographolide treated cells, compared
to the control or treated with carboplatin alone point to in-
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Figure 1 Clonogenic survival assay. MDA-MB-231 were treated with different concentrations of Andrographolide and 20 µM Carboplatin and
allowed for colony formation by replacement of the medium once in every three days for 7-12 days. The colonies formed were fixed in methanol,
stained with crystal violet and counted using Gene Tools, Syngene Imaging system. Figure 1a represents survival curve of MDA-MB-231 cells, 1b
represents bar diagram of the same. Figure 1c represent colonies stained with crystal violet i ) control, ii-vi ) 2, 4, 6, 8, and 10 M andrographolide.
Figure 1d represent colonies stained with crystal violet i) 20 M carboplatin, ii-vi) 2, 4, 6, 8,and 10 M andrographolide in the presence of 20  M
carboplatin. The blue bar represents andrographolide alone and red bar represents combination treatment of andrographolide and carboplatin.
The bars represent mean ± standard error
Figure 2 Cellcycle analysis and Nuclear Morphology. MDA-MB-231cells were exposed to 15 µM Andrographolideand 20 µM Carboplatin alone
and in combination. Cell cycle profiles wereassessed after 12 hr treatment by flow cytometry (FACS Calibur, BD Biosciences,CA). A minimum of
10,000 cells per sample were acquired and analyzed using CellQuest Pro software. Figure is a graphical representation of PI stained cells.Red
coloured areas represent cells in G0 and G2/M phasesrespectively; striked areas represent cells in S phase. The figure is arepresentative of
independent experiments conducted thrice
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Figure 3 Expression and Phosphorylation status of FANC D2, FANC J, pRPA32, RAD51, P53, and Acetyl P53. The expression and
phosphorylation status of these proteins were analyzed using specific antibodies. The figures are western blots and the various panels represent
the effects of 15  M Androgarpholide alone, 20  M Carboplatin and co-treatment of both. The blots represent three independent experiments.
creased apoptosis due to andrographolide. Androgarpholide was
found to further increase the cells in early and mid stages when
treated in combination with carboplatin. Cells treated with an-
drographolide alone, when stained with Propidium Iodide and
DAPI exhibited rounded and apoptotic cells whose number in-
creased in cells treated with combination of both (Fig ure.4c).
This strengthens the process of apoptosis as negative regulator
of cancer and chemotherapeutic nature of andrographolide as an
agent of effective synergistic treatments.
Discussion
Natural product, andrographolide and its analogs are widely
used as chemotherapeutic agents for various cancers [20].
However, the mechanism of the anti-tumor activities of an-
drographolide and its synergistic properties are not well defined
in breast cancer cells. Studies on andrographolide in many tu-
mor cell models have demonstrated the anti-neoplastic effects
which are partly due to the G2/M cell cycle arrest and apopto-
sis [21]. Recently, studies also suggested that andrographolide
induces DNA damage and cell cycle arrest in tumor cells [22].
In our study we explored its DNA damage inducing capability
in triple negative breast cancer cells i.e MDA-MB-231 cells.
The DNA damage induced by replication stress results in the
formation of stalled or collapsed forks, which further activates
the ATM/ATR-mediated cell cycle check point responses to
promote fork stability for repli cation through Rad18 and other
DNA repair mechanisms associated with Fanconi anemia [23].
Since such compounds are highly reactive in nature and influ-
ence the functionality and stability of many proteins in cells, the
prediction of the specific cellular targets responsible for DNA
damage becomes complex. In this regard, the present study
focused on DNA damage mediated effects of andrographolide
alone and in combination with carboplatin against MDA-MB-
231 breast cancer cells in a concentration-dependent manner
which showed a positive correlation.
Earlier studies shown that drug induced replication stress
leads to activation of the FA pathway, resulting in mono-
ubiquitination of FANCD2 and its nuclear foci forma-
tion [24, 25]. To study the effects of andrographolide, MDA-
MB-231 cells were treated with andrographolide alone. To
study its synergistic effects, we also treated cells with andro-
grapholide in combination with another drug named carboplatin.
The concentrations of carboplatin used did not induce apoptosis.
Andrographolide inhibited proliferation and enhanced anti-
proliferative property of carboplatin in breast cancer cells. Inter-
estingly, the study demonstrated that andrographolide interferes
with cell cycle progression by inducing replication-associated
DNA damage, as evidenced by increased number of cells in
S-phase and G2-M phase together with increased expression
of FANCJ, FANCD2, pRPA32, RAD 51 and p53. Studies have
shown that p53 is phosphorylated and acetylated in response to
DNA damage and repair mediated by ATM and ATR signaling
pathways. Our studies further confirmed the activation p53 by
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Figure 4 Analysis of apoptosis induced by andrographolide in breast cancer cells. MDA-MB-231 cells were exposed to 15 µM andrographolide, 20
µM carboplatin and combination of both for 48 hours and the cells were co-stained with Annexin V and PI antibody and analyzed by flow cytometry.
Fig: 4a represents graphical representation of different stages of apoptosis. The quadrants are i) Control, ii) Andrographolide, iii) Carboplatin and
iV) Androgarpholide and carboplatin respectively. 4b represents bar diagram of the same. 4C) Cells were stained with 20 g/ml Propidium Iodide
and mounted in mounatnt containing 0.5mg/ml 4, 6-diamidino-2-phenylindole (DAPI).and imaged at 40x magnification using Olympus fluorescent
microscope. Scale: 10m. The image is self explanatory
phosphorylation at ser15 and acetylation at Lys-382 in response
to DNA damage. Apoptosis induction was also observed in
cells treated with andrographolide confirming that DNA damag-
ing chemotherapeutic agents result in apoptosis to limit tumor
growth.
In conclusion, the data could establish an important basis for
the preclinical evaluation of andrographolide with and without
carboplatin in treatment of the breast cancer. Since chemother-
apy remains the common standard therapy for breast cancer es-
pecially triple negative breast cancer, it is proposed that andro-
grapholide may thus provide an important therapeutic effect, in
combination with chemotherapeutic drugs to potentially elimi-
nate locally metastasized breast cancer tumors. However, further
mechanistic studies are required for the molecular mechanisms
leading to apoptosis and cell death.
Conclusion
Andrograpolide induces cell cycle arrest and thereby cell death.
In addition andrographolide enhances anti tumorgenic effects of
carboplatin.
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